Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Optic Neuritis 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Myelitis, Transverse 1Multiple Sclerosis 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Cerebellar Diseases 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 217Rituximab 110Etoposide 99Peripheral Blood Stem Cell Transplantation 93Vincristine 91Filgrastim 91Methotrexate 90Cytarabine 90fludarabine phosphate 84Radiotherapy 67Doxorubicin 67Prednisone 66Dexamethasone 57Cyclosporine 53Mycophenolic Acid 52Whole-Body Irradiation 49Busulfan 46Melphalan 44blinatumomab 43fludarabine 41Tacrolimus 41Antilymphocyte Serum 40Methylprednisolone 39merphos 35Calcium Dobesilate 34Leucovorin 33Granulocyte Colony-Stimulating Factor 30Mercaptopurine 26dexamethasone acetate 25dexamethasone 21-phosphate 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Burkitt Lymphoma × Interferon beta-1a × Clear all
NCT05936229 2024-07-12

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Fred Hutchinson Cancer Center

Phase 1/2 Withdrawn
Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡